as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,399.7
Change
+0.7 (0.05%)
Open
₹1,402.9
Prev. Close
₹1,399.0
Day High
₹1,421.0
Day Low
₹1,388.4
Volume Analysis
Traded
1,166,527
Delivered
422,353
Delivery %
36.21%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Promoter holding is falling
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,450.26 | ₹1,435.63 | ₹1,417.66 | ₹1,403.03 | ₹1,385.06 | ₹1,370.43 | ₹1,352.46 |
| Fibonacci | ₹1,435.63 | ₹1,423.18 | ₹1,415.48 | ₹1,403.03 | ₹1,390.58 | ₹1,382.88 | ₹1,370.43 |
| Camarilla | ₹1,408.67 | ₹1,405.68 | ₹1,402.69 | ₹1,403.03 | ₹1,396.71 | ₹1,393.72 | ₹1,390.74 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-6.74%
1 Week
+0.98%
1 Month
-1.67%
3 Months
-4.48%
6 Months
+17.04%
1 Year
-6.65%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹678.43
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
9.77%
Net margin 11.85% × asset turnover 0.67x × equity multiplier 1.23x
Company Overview
Sector
Healthcare
Market Cap
₹111,060 Cr
P/E (TTM)
31.0
ROE
11.6%
Book Value
₹426.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Cipla Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (100/100), while Momentum (41/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
64/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 25.7%
- −The company has delivered a poor sales growth of 8.01% over past five years.
- −Promoter holding has decreased over last 3 years: -4.24%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Mr Venkata Sai Mungara shifts to Cipla USA Inc. role from 1 October 2026, ceasing as SMP.
Cipla received ESG rating of 68 from Niche.
Cipla and Qilu ink exclusive US licensing and supply deal for pembrolizumab biosimilar QL2107.
NCLT-directed notice on Inzpera Healthsciences merger with Cipla; objections invited within 30 days.
Please find attached newspaper publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 6,329 | 6,678 | 6,604 | 6,163 | 6,694 | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 |
| Expenses + | 4,835 | 4,944 | 4,856 | 4,847 | 4,978 | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 | 5,819 | 5,586 | 5,927 |
| Operating Profit | 1,494 | 1,734 | 1,748 | 1,316 | 1,716 | 1,886 | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 | 955 | 1,192 |
| OPM % | 24.0% | 26.0% | 26.0% | 21.0% | 26.0% | 27.0% | 28.0% | 23.0% | 26.0% | 25.0% | 18.0% | 15.0% | 17.0% |
| Other Income + | 136 | 176 | -10 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | -70 | 148 | 211 |
| Interest | 16 | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 |
| Depreciation | 239 | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 |
| Profit before tax | 1,375 | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 |
| Tax % | 28.0% | 28.0% | 28.0% | 26.0% | 27.0% | 27.0% | 17.0% | 19.0% | 27.0% | 27.0% | 24.0% | 22.0% | 27.0% |
| Net Profit + | 998 | 1,155 | 1,068 | 932 | 1,175 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 |
| EPS in Rs | 12 | 14 | 13 | 12 | 15 | 16 | 19 | 15 | 16 | 17 | 8 | 7 | 10 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 11,345 | 13,790 | 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 | 28,324 |
| Expenses + | 9,183 | 11,310 | 11,898 | 12,329 | 13,265 | 13,926 | 14,907 | 17,211 | 17,726 | 19,483 | 20,420 | 22,280 | 23,027 |
| Operating Profit | 2,163 | 2,480 | 2,496 | 2,826 | 3,097 | 3,206 | 4,252 | 4,553 | 5,027 | 6,291 | 7,128 | 5,883 | 5,297 |
| OPM % | 19.0% | 18.0% | 17.0% | 19.0% | 19.0% | 19.0% | 22.0% | 21.0% | 22.0% | 24.0% | 26.0% | 21.0% | 19.0% |
| Other Income + | 164 | 208 | 208 | 280 | 477 | 344 | 266 | 99 | 293 | 552 | 862 | 606 | 558 |
| Interest | 168 | 207 | 159 | 114 | 168 | 197 | 161 | 106 | 110 | 90 | 62 | 54 | 57 |
| Depreciation | 505 | 754 | 1,323 | 1,323 | 1,326 | 1,175 | 1,068 | 1,052 | 1,172 | 1,051 | 1,107 | 1,211 | 1,262 |
| Profit before tax | 1,654 | 1,727 | 1,222 | 1,669 | 2,079 | 2,178 | 3,290 | 3,493 | 4,038 | 5,702 | 6,821 | 5,224 | 4,536 |
| Tax % | 24.0% | 19.0% | 15.0% | 15.0% | 27.0% | 29.0% | 27.0% | 27.0% | 30.0% | 27.0% | 22.0% | 26.0% | — |
| Net Profit + | 1,229 | 1,383 | 1,035 | 1,417 | 1,492 | 1,500 | 2,389 | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 | 3,356 |
| EPS in Rs | 15 | 17 | 13 | 18 | 19 | 19 | 30 | 31 | 35 | 51 | 65 | 48 | 42 |
| Dividend Payout % | 14.0% | 12.0% | 16.0% | 17.0% | 16.0% | 21.0% | 17.0% | 16.0% | 24.0% | 25.0% | 25.0% | 27.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 10,641 | 11,356 | 12,383 | 14,068 | 14,851 | 15,602 | 18,165 | 20,680 | 23,246 | 26,545 | 31,032 | 34,270 |
| Borrowings + | 1,703 | 5,202 | 4,113 | 4,098 | 4,316 | 2,816 | 2,014 | 1,056 | 803 | 559 | 438 | 614 |
| Other Liabilities + | 3,166 | 4,331 | 4,213 | 4,346 | 4,433 | 4,843 | 4,514 | 4,960 | 5,089 | 5,267 | 5,702 | 7,297 |
| Total Liabilities | 15,670 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,300 | 32,533 | 37,334 | 42,343 |
| Fixed Assets + | 6,830 | 9,368 | 9,492 | 9,950 | 9,608 | 9,683 | 9,516 | 9,683 | 9,160 | 9,607 | 10,006 | 12,434 |
| CWIP | 581 | 2,061 | 1,683 | 981 | 676 | 825 | 969 | 766 | 1,093 | 1,153 | 1,566 | 2,042 |
| Investments | 640 | 759 | 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 | 5,449 | 7,933 | 8,223 |
| Other Assets + | 7,620 | 8,862 | 8,721 | 10,483 | 10,923 | 11,444 | 11,661 | 13,857 | 15,384 | 16,323 | 17,828 | 19,643 |
| Total Assets | 15,670 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,300 | 32,533 | 37,334 | 42,343 |
| Equity Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 | 162 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | 4,134 | 5,005 | 3,940 |
| Cash from Investing Activity + | -950 | -4,533 | -1,304 | -834 | -1,688 | 114 | -2,374 | -1,858 | -2,376 | -2,982 | -3,682 | -2,234 |
| Cash from Financing Activity + | 165 | 3,104 | -1,326 | -385 | -349 | -2,949 | -1,240 | -1,600 | -958 | -1,200 | -1,293 | -1,234 |
| Net Cash Flow | 388 | 312 | -248 | 243 | -345 | 234 | 141 | -132 | -97 | -49 | 30 | 473 |
| CFO/OP | 72 | 91 | 113 | 77 | 74 | 122 | 113 | 98 | 90 | 91 | 94 | 94 |
| Free Cash Flow | 548 | 688 | 1,284 | 723 | 1,187 | 2,083 | 2,964 | 2,645 | 2,102 | 2,819 | 3,490 | 928 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 16.68% | 16.53% | 16.36% | 16.4% | 16.11% | 16.43% | 16.36% | 16.3% | 15.99% | 16.12% | 16.26% | 15.93% |
| Promoters | 33.46% | 33.46% | 33.46% | 30.91% | 30.93% | 29.19% | 29.2% | 29.19% | 29.22% | 29.22% | 29.22% | 29.22% |
| Government | 0.21% | 0.21% | 0.21% | 0.21% | 0.21% | 0.23% | 0.26% | 0.27% | 0.27% | 0.27% | 0.27% | 0.28% |
| FII | 25.74% | 25.73% | 25.82% | 27.82% | 28.8% | 26.65% | 26.28% | 25.24% | 24.54% | 23.93% | 22.55% | 20.2% |
| DII | 23.9% | 24.05% | 24.15% | 24.66% | 23.95% | 27.49% | 27.89% | 28.98% | 29.98% | 30.45% | 31.71% | 34.35% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Cipla Ltd (this stock) | 111,060 | 31.0 | 3.23 | 11.6% |
| Laurus Labs Limited | 108,438 | 99.2 | 20.44 | 18.3% |
| Zydus Lifesciences Ltd | 115,890 | 23.8 | 4.32 | 21.2% |
| Mankind Pharma Limited | 102,225 | 47.9 | 6.27 | 13.1% |
| Dr. Reddy S Laboratories | 101,096 | 31.4 | 2.67 | 11.2% |
| Aurobindo Pharma Ltd | 98,939 | 26.2 | 2.64 | 10.1% |
| Max Healthcare Ins Ltd | 98,694 | 65.9 | 9.22 | 14.7% |
Which Mutual Funds Hold Cipla Ltd?
Frequently Asked Questions about Cipla Ltd
Cipla Ltd (CIPLA) closed at ₹1,399.7 on NSE on 25 September 2026, up 0.7 (0.05%) from the previous close.
Cipla Ltd trades on the NSE (National Stock Exchange of India) under the symbol CIPLA.
Cipla Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 31.0.
Cipla Ltd has a dividend yield of 0.94%.
Cipla Ltd's 52-week high is ₹1,673.0 and its 52-week low is ₹1,166.0.
Cipla Ltd has a market capitalisation of ₹111,060 crore.
Cipla Ltd has a TopFund Quality Score of 64/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Cipla Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.